# ALPINE IMMUNE SCIENCES INC (ALPN)

> Institutional ownership reported to the SEC as of Q1 2024, from Form 13F filings. Source: https://holderbook.com/stocks/ALPN/

- Reporting holders: 179
- Reported value: $2.6B
- Held through calls: 0.2%
- Held through puts: 0.4%

A 13F reports long US equity positions only. Shorts, bonds, foreign listings and cash are not visible here, and positions are disclosed up to 45 days after the quarter ends.

## Largest holders

| Manager | Value | Shares | Share of their book | Quarters held |
|---|---|---|---|---|
| [Decheng Capital LLC](https://holderbook.com/funds/2010850-decheng-capital-llc/) | $329.7M | 8,317,924 | 44.2% | 2 |
| [Avoro Capital Advisors LLC](https://holderbook.com/funds/1633313-avoro-capital-advisors-llc/) | $228.9M | 5,775,000 | 2.7% | 1 |
| [BlackRock Inc.](https://holderbook.com/funds/1364742-blackrock-inc/) | $141.7M | 3,575,092 | 0.0% | 22 |
| [Frazier Life Sciences Management, L.P.](https://holderbook.com/funds/1892134-frazier-life-sciences-management-l-p/) | $124.1M | 3,131,008 | 5.2% | 9 |
| [PRICE T ROWE ASSOCIATES INC /MD/](https://holderbook.com/funds/80255-price-t-rowe-associates-inc-md/) | $122.1M | 3,080,220 | 0.0% | 7 |
| [STATE STREET CORP](https://holderbook.com/funds/93751-state-street-corp/) | $112.8M | 2,845,839 | 0.0% | 12 |
| [VANGUARD GROUP INC](https://holderbook.com/funds/102909-vanguard-group-inc/) | $107.5M | 2,712,285 | 0.0% | 22 |
| [Cormorant Asset Management, LP](https://holderbook.com/funds/1583977-cormorant-asset-management-lp/) | $107.0M | 2,700,000 | 4.7% | 3 |
| [ORBIMED ADVISORS LLC](https://holderbook.com/funds/1055951-orbimed-advisors-llc/) | $106.3M | 2,680,496 | 2.0% | 22 |
| [MORGAN STANLEY](https://holderbook.com/funds/895421-morgan-stanley/) | $93.9M | 2,368,935 | 0.0% | 16 |
| [Lynx1 Capital Management LP](https://holderbook.com/funds/1910456-lynx1-capital-management-lp/) | $89.3M | 2,253,183 | 23.0% | 10 |
| [Paradigm Biocapital Advisors LP](https://holderbook.com/funds/1855655-paradigm-biocapital-advisors-lp/) | $84.1M | 2,121,163 | 3.0% | 9 |
| [Darwin Global Management, Ltd.](https://holderbook.com/funds/1839209-darwin-global-management-ltd/) | $78.6M | 1,982,016 | 10.5% | 1 |
| [COMMODORE CAPITAL LP](https://holderbook.com/funds/1831942-commodore-capital-lp/) | $54.5M | 1,375,000 | 3.6% | 7 |
| [Octagon Capital Advisors LP](https://holderbook.com/funds/1839435-octagon-capital-advisors-lp/) | $49.2M | 1,241,300 | 5.9% | 7 |
| [Avidity Partners Management LP](https://holderbook.com/funds/1791827-avidity-partners-management-lp/) | $46.6M | 1,174,700 | 1.5% | 1 |
| [GREAT POINT PARTNERS LLC](https://holderbook.com/funds/1281446-great-point-partners-llc/) | $44.7M | 1,128,499 | 7.0% | 8 |
| [FRANKLIN RESOURCES INC](https://holderbook.com/funds/38777-franklin-resources-inc/) | $43.3M | 1,093,203 | 0.0% | 2 |
| [GEODE CAPITAL MANAGEMENT, LLC](https://holderbook.com/funds/1214717-geode-capital-management-llc/) | $36.1M | 910,599 | 0.0% | 22 |
| [TWO SIGMA ADVISERS, LP](https://holderbook.com/funds/1478735-two-sigma-advisers-lp/) | $26.5M | 668,775 | 0.1% | 15 |
| [Vivo Capital, LLC](https://holderbook.com/funds/1674712-vivo-capital-llc/) | $20.8M | 520,505 | 1.6% | 4 |
| [TWO SIGMA INVESTMENTS, LP](https://holderbook.com/funds/1179392-two-sigma-investments-lp/) | $20.6M | 519,971 | 0.0% | 4 |
| [Nuveen Asset Management, LLC](https://holderbook.com/funds/1521019-nuveen-asset-management-llc/) | $20.3M | 513,175 | 0.0% | 12 |
| [First Light Asset Management, LLC](https://holderbook.com/funds/1600004-first-light-asset-management-llc/) | $19.9M | 501,243 | 1.5% | 1 |
| [JANUS HENDERSON GROUP PLC](https://holderbook.com/funds/1274173-janus-henderson-group-plc/) | $17.8M | 450,827 | 0.0% | 2 |

## Quarter by quarter

| Quarter | Holders | Reported value |
|---|---|---|
| Q1 2024 | 179 | $2.6B |
| Q4 2023 | 134 | $1.1B |
| Q3 2023 | 89 | $526.1M |
| Q2 2023 | 77 | $380.4M |
| Q1 2023 | 59 | $267.7M |
| Q4 2022 | 62 | $251.5M |
| Q3 2022 | 69 | $284.0M |
| Q2 2022 | 57 | $204.4M |
| Q1 2022 | 57 | $221.9M |
| Q4 2021 | 53 | $257.3M |
| Q3 2021 | 44 | $163.5M |
| Q2 2021 | 47 | $118.5M |